Infliximab

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing, SpA

Trial Timeline

Jan 1, 2008 → Nov 1, 2008

NCT ID

NCT00686894

About Infliximab

Infliximab is a approved stage product being developed by Merck for Spondylitis, Ankylosing. The current trial status is terminated. This product is registered under clinical trial identifier NCT00686894. Target conditions include Spondylitis, Ankylosing, SpA.

What happened to similar drugs?

10 of 20 similar drugs in Spondylitis, Ankylosing were approved

Approved (10) Terminated (3) Active (9)

🔄adalimumabEisaiPhase 3

❌Ixekizumab + Placebo + AdalimumabEli LillyPhase 3

✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved

🔄Golimumab + PlaceboJohnson & JohnsonPhase 3

✅GolimumabJohnson & JohnsonApproved

🔄infliximab + PlaceboMerckPhase 3

✅InfliximabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01349920	Pre-clinical	Completed	Nov 28, 2012	Sep 28, 2015	Crohn Disease
NCT01148901	Approved	Withdrawn	Jun 1, 2010	Dec 1, 2010	Ankylosing Spondylitis
NCT00988832	Pre-clinical	Completed	Feb 1, 2010	Dec 1, 2010	Crohn's Disease
NCT00779675	Pre-clinical	Completed	Oct 1, 2008	Aug 1, 2012	Psoriasis
NCT00686894	Approved	Terminated	Jan 1, 2008	Nov 1, 2008	Spondylitis, Ankylosing
NCT00741104	Pre-clinical	Completed	Jan 1, 2008	Jun 1, 2008	Rheumatoid Arthritis
NCT00686686	Phase 3	Completed	Dec 1, 2007	Apr 1, 2009	Psoriasis
NCT00686595	Approved	Completed	Oct 1, 2007	Oct 1, 2009	Psoriasis
NCT00749398	Pre-clinical	Completed	Sep 1, 2007	Sep 1, 2010	Psoriasis
NCT00725452	Pre-clinical	Completed	Oct 1, 2006	Jun 1, 2010	Psoriasis
NCT00687401	Phase 3	Completed	Jun 1, 2006	May 1, 2009	Psoriasis
NCT00687362	Phase 2	Completed	May 30, 2006	Nov 11, 2008	Psoriasis
NCT00727298	Pre-clinical	Completed	Feb 1, 2006	Aug 1, 2011	Arthritis, Rheumatoid
NCT00724243	Pre-clinical	Completed	Jan 1, 2006	Oct 1, 2008	Rheumatoid Arthritis
NCT00705289	Pre-clinical	Completed	Dec 1, 2005	Sep 1, 2008	Rheumatoid Arthritis
NCT00254982	Phase 3	Completed	Aug 1, 2005	Sep 1, 2006	Psoriasis
NCT00705471	Pre-clinical	Terminated	Apr 1, 2005	Sep 1, 2007	Crohn Disease
NCT00724958	Pre-clinical	Completed	Dec 1, 2004	Jul 1, 2010	Crohn's Disease
NCT00779012	Approved	Completed	Oct 1, 2004	Jun 1, 2007	Spondylitis, Ankylosing
NCT00725543	Pre-clinical	Completed	Jun 1, 2004	Jun 1, 2010	Spondylitis, Ankylosing

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors

Product	Company	Stage	Hype Score
Infliximab	Celltrion	Phase 1	29
Infliximab	Celltrion	Phase 1	29
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
adalimumab	Eisai	Phase 3	40
Ixekizumab + Placebo + Adalimumab	Eli Lilly	Phase 3	32
Tramadol /acetaminophen + Diclofenac	Johnson & Johnson	Approved	35
Golimumab + Placebo	Johnson & Johnson	Phase 3	40
Golimumab	Johnson & Johnson	Approved	43
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 2/3	38
placebo for risankizumab + risankizumab	AbbVie	Phase 2	35
Upadacitinib + Placebo	AbbVie	Phase 2	35
Adalimumab	AbbVie	Pre-clinical	26
infliximab + Placebo	Merck	Phase 3	40
Infliximab	Merck	Approved	35
Infliximab + Placebo + Naproxen	Merck	Phase 3	40
Infliximab	Merck	Pre-clinical	26
Golimumab	Merck	Approved	43
Remicade	Merck	Approved	43
Remicade	Merck	Approved	43
Infliximab	Merck	Approved	43